Xtant Medical entered into a private label distribution agreement with curasan to distribute Matriform synthetic scaffolds in North America.
Matriform, comprising Beta-Tricalcium Phosphate and porcine collagen, allows Xtant to enter the bone graft substitute market. The company’s biologic lineup already includes demineralized bone matrix, allografts and a placental tissue matrix.
Matriform will be offered in flexible strip and moldable formats. The formulas received FDA 510(k) clearance at the end of 2016 (under the name CERASORB Ortho Foam), and have been used in Europe for >20 years.
Source: Xtant Medical Holdings, Inc.
Xtant Medical entered into a private label distribution agreement with curasan to distribute Matriform synthetic scaffolds in North America.
Matriform, comprising Beta-Tricalcium Phosphate and porcine collagen, allows Xtant to enter the bone graft substitute market. The company's biologic lineup already includes demineralized bone...
Xtant Medical entered into a private label distribution agreement with curasan to distribute Matriform synthetic scaffolds in North America.
Matriform, comprising Beta-Tricalcium Phosphate and porcine collagen, allows Xtant to enter the bone graft substitute market. The company’s biologic lineup already includes demineralized bone matrix, allografts and a placental tissue matrix.
Matriform will be offered in flexible strip and moldable formats. The formulas received FDA 510(k) clearance at the end of 2016 (under the name CERASORB Ortho Foam), and have been used in Europe for >20 years.
Source: Xtant Medical Holdings, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.